Rona Therapeutics Announces Breakthrough Data On Potential Annual Dosing Rnai Therapy RN026 Targeting Lipoprotein(A) In The National Lipid Association (NLA) Scientific Sessions 2025

2025-05-29 08:01:37

(MENAFN- PR Newswire)

SHANGHAI, May 29, 2025 /PRNewswire/ -- Rona Therapeutics, a global leading RNA therapy company, today announced preclinical data for its self-developed RNA interference (RNAi) therapy RN026 at the National Lipid Association (NLA) Annual Scientific Sessions. Preclinical studies revealed that the therapy, targeting lipoprotein(a) (Lp(a))-an independent risk factor for cardiovascular diseases- achieved a 99% reduction in Lp(a) with potential annual dosing regimen in non-human primate (NHP) study .

Key Highlights

Unparalleled Efficacy and Durability

In transgenic mouse models, a single 2mg/kg subcutaneous injection resulted in 98% reduction in serum Apo(a) protein, which lasted for at least 42 days
In NHP study, a single 2mg/kg subcutaneous injection achieved maximum 99% reduction of serum Lp(a); 95% Lp(a) reduction was maintained at 98 days post-dose with ~80% serum Lp(a) decreasing effect sustained till 154 days , suggesting annual dosing potential in human

Precision siRNA Design

Targets multiple sites inside and outside of the KIV-2 CNV region to maximize knock-down efficiency
Very low hybridization related off-target risk

Dual Benefits

Accompanied by a 25% reduction in LDL-C levels in NHP study
Repeated dose tox studies in SD rats confirmed no adverse findings

About RN026

RN026 demonstrates tremendous potential as a breakthrough therapy in a range of cardiovascular diseases, i.e. ASCVD, aortic stenosis, peripheral arterial disease, with differentiated long-lasting efficacy, potent Lp(a) reduction, and excellent safety profile. There is approximately 10-20% world population that has elevated serum Lp(a) level. RN026 is poised to bring new therapeutic hope to cardiovascular patients globally.

About Rona Therapeutics

Rona Therapeutics is a global leader in nucleic acid innovative drug platform company, specializing in the treatment of cardiometabolic diseases, obesity and neurological diseases with proprietary oligo chemistry and delivery platform. Rona Therapeutics is committed to developing the best and first-in-class siRNA drugs with differentiation and innovation to address unmet needs and improve outcome in cardiovascular diseases, obesity, and MASH.

SOURCE Rona Therapeutics

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+
Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

MENAFN29052025003732001241ID1109610735

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.